Section Arrow
ADTX.NASDAQ
- Aditxt Inc
Quotes are at least 15-min delayed:2025/11/04 09:13 EST
Pre Market
Last
 5.74
-0.77 (-11.83%)
Bid
5.75
Ask
5.85
High 6.53 
Low 5.62 
Volume 24899 
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
6.51 
1-M High
85.0212 
Volume 
-- 
Bid
5.75
Ask
5.85
Day Low
-- 
Open
-- 
1-M Low
5.1542 
Market Cap 
32.40M 
Currency USD 
P/E
%Yield -- 
10-SMA 19.58 
20-SMA 39.34 
50-SMA 73 
52-W High 11,941.275 
52-W Low 1.0301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2,942.24/-93.53
Enterprise Value
32.83M
Balance Sheet
Book Value Per Share
2.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
133.99K
Operating Revenue Per Share
0.19
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
Pre Market 18.38 -0.51 -2.70%
ZVRAZevra Therapeutics----0.000%-- 
Pre Market 10.19 -0.02 -0.20%
ZURAZura Bio Limited----0.000%5.54PE
Pre Market 3.5501 -0.1299 -3.53%
ZNTLZentalis Pharmaceuticals----0.000%-- 
Pre Market 1.43 -0.01 -0.69%
ZLABZai Lab Limited----0.000%-- 
Pre Market 26.06 -0.69 -2.58%
Quotes are at least 15-min delayed:2025/11/04 09:13 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.